NEW YORK (GenomeWeb) – CareDx reported after the close of the market on Wednesday that its second quarter revenues rose 51 percent year over year thanks to record volumes of its AlloMap non-invasive blood test for heart transplant patients.

For the three months ended June 30, the firm reported total revenues of $10.7 million, up from $7.1 million a year ago, and narrowly beating the consensus Wall Street estimate for revenues of $10.4 million.

To read the full story....

Register for Free.

Already have a GenomeWeb or 360Dx account?
Login Now.

Robert Redfield is floated as the next director of the US Centers for Disease Control and Prevention, the Washington Post reports.

The New York Times writes that the National Institutes of Health's All of Us Research Program is "ambitious" and that some are concerned it might be overly so.

Representative Lamar Smith's criticism of the National Science Foundation has "changed the nature of the conversation," according to ScienceInsider.

In PLOS this week: non-coding RNA function in yeast, transcriptomic profiles of malaria parasites, and more.